W Chen1, B Paulus, D Shu, V Chadwick. 1. Wakefield Gastroenterology Research Institute, Wakefield Hospital, Wellington South, New Zealand. w.chen@clear.net.nz
Abstract
BACKGROUND: The CC-chemokines eotaxin and eotaxin-2, produced by epithelial and phagocytic cells, are potent and selective chemoattractants for eosinophils and basophils. The eosinophil is a potent inflammatory cell thought to play an important role in the pathogenesis of inflammatory bowel disease (IBD). In this study we investigated the serum concentrations of eotaxin and eotaxin-2 in patients with Crohn disease and ulcerative colitis. METHODS: Thirty-one patients with Crohn disease, 35 patients with ulcerative colitis and 41 control patients were studied. Eotaxin and eotaxin-2 serum levels were measured with solid phase sandwich enzyme-linked immunosorbent assays. RESULTS: Significantly increased serum eotaxin levels were observed in both patients with Crohn disease (289.4+/-591.5 pg/ml) and ulcerative colitis (207.0+/-243.4 pg/ml) when compared with controls (138.0+/-107.8 pg/ml) (P < 0.01). Moreover, patients with active Crohn disease and ulcerative colitis showed significantly higher serum eotaxin levels than patients with quiescent disease (434.0+/-776.8 pg/ml versus 113.8+/-65.4 pg/ml in Crohn disease and 295.7+/-337.1 versus 121.2+/-91.9 pg/ml in ulcerative colitis, P < 0.05). In contrast, there was no significant difference in eotaxin-2 serum levels among patients with Crohn disease (863.5+/-448.2 pg/ml), ulcerative colitis (1028.3+/-431.4 pg/ml) and controls (981.4+/-539.4 pg/ml). CONCLUSIONS: Eotaxin is significantly increased in serum of patients with active Crohn disease and ulcerative colitis, suggesting that this cytokine may play a role in the pathogenesis of IBD.
BACKGROUND: The CC-chemokines eotaxin and eotaxin-2, produced by epithelial and phagocytic cells, are potent and selective chemoattractants for eosinophils and basophils. The eosinophil is a potent inflammatory cell thought to play an important role in the pathogenesis of inflammatory bowel disease (IBD). In this study we investigated the serum concentrations of eotaxin and eotaxin-2 in patients with Crohn disease and ulcerative colitis. METHODS: Thirty-one patients with Crohn disease, 35 patients with ulcerative colitis and 41 control patients were studied. Eotaxin and eotaxin-2 serum levels were measured with solid phase sandwich enzyme-linked immunosorbent assays. RESULTS: Significantly increased serum eotaxin levels were observed in both patients with Crohn disease (289.4+/-591.5 pg/ml) and ulcerative colitis (207.0+/-243.4 pg/ml) when compared with controls (138.0+/-107.8 pg/ml) (P < 0.01). Moreover, patients with active Crohn disease and ulcerative colitis showed significantly higher serum eotaxin levels than patients with quiescent disease (434.0+/-776.8 pg/ml versus 113.8+/-65.4 pg/ml in Crohn disease and 295.7+/-337.1 versus 121.2+/-91.9 pg/ml in ulcerative colitis, P < 0.05). In contrast, there was no significant difference in eotaxin-2 serum levels among patients with Crohn disease (863.5+/-448.2 pg/ml), ulcerative colitis (1028.3+/-431.4 pg/ml) and controls (981.4+/-539.4 pg/ml). CONCLUSIONS:Eotaxin is significantly increased in serum of patients with active Crohn disease and ulcerative colitis, suggesting that this cytokine may play a role in the pathogenesis of IBD.
Authors: P Manousou; G Kolios; V Valatas; I Drygiannakis; L Bourikas; K Pyrovolaki; I Koutroubakis; H A Papadaki; E Kouroumalis Journal: Clin Exp Immunol Date: 2010-11 Impact factor: 4.330
Authors: Sigrun Renate Hofmann; Anne Sophie Kubasch; Ursula Range; Martin Walther Laass; Henner Morbach; Hermann Joseph Girschick; Christian Michael Hedrich Journal: Rheumatol Int Date: 2016-03-21 Impact factor: 2.631
Authors: Richard Ahrens; Amanda Waddell; Luqman Seidu; Carine Blanchard; Rebecca Carey; Elizabeth Forbes; Maria Lampinen; Tara Wilson; Elizabeth Cohen; Keith Stringer; Edgar Ballard; Ariel Munitz; Huan Xu; Nancy Lee; James J Lee; Marc E Rothenberg; Lee Denson; Simon P Hogan Journal: J Immunol Date: 2008-11-15 Impact factor: 5.422
Authors: Benjamin Click; Alyce M Anderson; Ioannis E Koutroubakis; Claudia Ramos Rivers; Dmitriy Babichenko; Jorge D Machicado; Douglas J Hartman; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Arthur Barrie; Sally E Wenzel; Miguel Regueiro; David G Binion Journal: Am J Gastroenterol Date: 2017-11-07 Impact factor: 10.864
Authors: Angélica T Vieira; Caio T Fagundes; Ana Leticia Alessandri; Marina G M Castor; Rodrigo Guabiraba; Valdinéria O Borges; Kátia Daniella Silveira; Erica L M Vieira; Juliana L Gonçalves; Tarcilia A Silva; Maud Deruaz; Amanda E I Proudfoot; Lirlândia P Sousa; Mauro M Teixeira Journal: Am J Pathol Date: 2009-11-05 Impact factor: 4.307